SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
N/A
A prospective, longitudinal, multicentre, observational cohort follow-up st...
Status
Unknown
Location
Nouvelle Clinique BONNEFON
Start Date
2022-11-24
Trial ID
NCT05598684
Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions
PHASE1
This is an open-labeled (laboratory blinded), randomized, two period, singl...
Status
Unknown
Location
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl"
Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)
PHASE1
Comparative randomized, single dose, three-way, three-sequence, two treatme...